Terrie Curran is the president of global inflammation & immunology at Celgene, having previously served as president, worldwide markets I&I until April 1 of this year.
Prior to joining Celgene in 2013, Terrie was Merck’s senior vice president and general manager of the global women’s health franchise, where she had commercial responsibility for $3 billion business, spanning the categories of contraception, fertility, HRT and osteoporosis. In 2012, the UNFPA honored her with an award for the Health and Dignity of Women and Girls.
With over 22 years of experience in the healthcare industry, Terrie has worked across many therapeutic categories including immunology, gastro-enterology, oncology, ophthalmology, metabolic and pain and women’s health. In addition to Celgene and Merck, she has held senior leadership roles with Schering-Plough, including with both their Switzerland and Australia/New Zealand offices, as well as a variety of sales, marketing, and management roles at the former Pharmacia.
A native Australian, Terrie holds both a B.S. and a graduate diploma in marketing from the University of Technology in Sydney, Australia.
In November of 2016, Terrie was appointed to the board of directors of Myovant Sciences, Ltd., and also served on the board of directors for H. Lundbeck A/S.